WORCKHARDT
Article Abstract:
Wockhardt Ltd posted a net profit of Rs363 million for the 6 months ended December 1997. It has set up five facilities including a day care centre in Calcutta and a hospital in Bangalore. The company exports bulk drugs. Its main formulations include Pelox Spasmo-Proxyvon, Zedex, Wokadine, Kaizem CD, Myodura and Pyrexon. Wockhardt plans to acquire the Tata Group's 50 percent stake in Merind. This will increase its product portfolio. The capacity of its Ankhleshwar unit is to be increased by 40 tonnes per annum. Its sales is likely to increase by 25-30 percent in the next three years. (rk) ------------------------------------------------------------ Financial Performance of Wockhardt Ltd (Rs in million) ------------------------------------------------------------ Particulars Year ended 6 months ended June 1997 December 1997 ------------------------------------------------------------ Sales 3,125.00 2,127.00 ------------------------------------------------------------ Gross profit 783.00 444.00 ------------------------------------------------------------ Net profit 621.00 363.00 ------------------------------------------------------------ Equity 351.00 351.00 ------------------------------------------------------------ Earnings per share (Rs) 17.70 20.70 ------------------------------------------------------------ Market price of share (Rs) 248.60 248.60 ------------------------------------------------------------
Comment:
Will likely increase sales by 25-30% in the next three years
Publication Name: Financial Express Investment Week
Subject: Business, international
ISSN: 0015-2005
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
PHARMACEUTICALS: SWEET PILL FOR INVESTORS
Article Abstract:
Glaxo posted a net profit of Rs411.9 million for the year ended December 1997. Glaxo has postponed its merger with Burroughs Wellcome due to pay disparities. Glaxo is a 51 percent subsidiary of Glaxo Wellcome Plc, UK. For the year ended December 31, 1997, it recorded a seven percent growth in sales. Glaxo plans to acquire the Rs400 million Biddle Sawyer, which has three facilities in Mumbai. Glaxo and Burroughs comarket their formulations in the domestic market. Its major brands include Betnesol, Septran, Phexin, Zinetac, Calpol and Cobadex. (rk) ------------------------------------------------------------ Financial Performance of Glaxo (Rs in million) ------------------------------------------------------------ Particulars Year ended December 1997 ------------------------------------------------------------ Sales 6,960.1 ------------------------------------------------------------ Gross profit 1,101.6 ------------------------------------------------------------ Net profit 411.9 ------------------------------------------------------------ Equity 597.8 ------------------------------------------------------------ Earnings per share (Rs) 6.9 ------------------------------------------------------------ Market price of share (Rs) 416.0 ------------------------------------------------------------
Comment:
Records a 7% growth in sales to Rs6,960.1 mil for the year ended 12/31/97
Publication Name: Financial Express Investment Week
Subject: Business, international
ISSN: 0015-2005
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
NICHOLAS PIRAMAL
Article Abstract:
Nicholas Piramal India Ltd (NPIL) posted net profit of Rs565.40 million for 1997-98. NIPL has hived off its glass business into a separate company, Gujarat Glass Limited with effect from April 1, 1998. NPIL focuses on formulations, comprising products of Roche and Boehringer Mannheim. It plans to hive off its bulk drugs division into a separate company, Global Fine Chemicals Pvt Ltd. It has a marketing tie-up with Stryker, US and joint ventures with Scholl of the UK for foot care products, Allergen of the US for eye care products and Cytran of the US for anti-TB products. (rk) ------------------------------------------------------------ Financial Performance of Nicholas Piramal India Ltd (Rs in million) ------------------------------------------------------------ Particulars 1997-98 ------------------------------------------------------------ Sales 5,346.40 ------------------------------------------------------------ Gross profit 964.90 ------------------------------------------------------------ Net profit 565.40 ------------------------------------------------------------ Equity 277.10 ------------------------------------------------------------ Earnings per share (Rs) 20.40 ------------------------------------------------------------ Market price of share (Rs) 429.75 ------------------------------------------------------------
Comment:
Posts net profit of Rs565.40 mil on sales of Rs5,346.40 mil for 1997-98
Publication Name: Financial Express Investment Week
Subject: Business, international
ISSN: 0015-2005
Year: 1998
User Contributions:
Comment about this article or add new information about this topic: